Table 1.
Study patients.
| Exosome Quantification Cohort | Immunohistochemistry Cohort | |||||
|---|---|---|---|---|---|---|
| PDAC (n=13) | IPMNca (n=4) | IPMN (n=4) | Benign (n=5) | PDAC (n=27) | IPMN (n=12) | |
| Age | 66 (54-86) | 67 (54-76) | 77 (61-81) | 76 (57-92) | 66 (45-87) | 71 (50-81) |
| Male | 9 (69%) | 2 (50%) | 1 (25%) | 2 (40%) | 17 (63%) | 7 (58%) |
| CA 19-9, unit/mL | 176 (16-921) | 14 (13-42) | 19 | 29 (16-69) | 251 (21-9337) | 45 (4-89) |
| Biliary stent | 5 (38%) | 1 (25%) | 0 (0%) | 1 (20%) | 14 (52%) | 0 (0%) |
| Whipple | 12 (92%) | 4 (100%) | 2 (50%) | 4 (80%) | 27 (100%) | 12 (100%) |
| Pathologic diagnosis | 13 (100%) PDAC | 1 (25%) BD 3 (75%) MD |
1 (25%) BD 3 (75%) MD |
3 (60%) pancreatitis 1 (20%) adenoma 1 (20%) cyst |
27 (100%) PDAC | 3 (25%) BD 9 (75%) MD |
| TNM stage | -- | |||||
| IA | 2 (15%) | 2 (50%) | -- | -- | 0 (0%) | |
| IIA | 3 (23%) | 1 (25%) | 7 (26%) | |||
| IIB | 8 (62%) | 1 (25%) | 20 (74%) | |||
| Tumor size, cm | 2.5 (0.6-4) | 0.8 (0.3-4) | 2.6 (1.3-3.2) | -- | 2.4 (1.3-5) | 1.9 (1.2-3.5) |
| Differentiation/dysplasia | ||||||
| Moderate/intermediate | 5 (38%) | 1 (25%) | 3 (75%) | -- | 13 (48%) | 3 (25%) |
| Poor/high | 8 (62%) | 3 (75%) | 1 (25%) | -- | 13 (48%) | 6 (50%) |
| PanIN | ||||||
| 1-2 | 2 (15%) | 1 (25%) | 2 (50%) | 4 (80%) | 6 (22%) | 3 (25%) |
| 3 | 9 (69%) | 0 (0%) | 0 (0%) | 0 (0%) | 17 (63%) | 0 (0%) |
| Lymphovascular invasion | 11 (85%) | 0 (0%) | -- | -- | 20 (74%) | -- |
| Perineural invasion | 12 (92%) | 0 (0%) | -- | -- | 24 (89%) | -- |
PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm; IPMNca, IPMN with microinvasive cancer; BD, branch duct IPMN; MD, main duct IPMN; TNM, tumor node metastasis; PanIN, pancreatic intraepithelial neoplasia
Categorical variables are expressed as frequency (percentage) and continuous variables are expressed as median (range).